West Pharmaceutical stock (US9523901012): Morgan Stanley fine-tunes target as WST trades near USD 320

West Pharmaceutical shares on the NYSE hovered around USD 320 on 05/29/2026 after Morgan Stanley nudged its price target to USD 325 with an equal-weight rating, keeping the focus on valuation rather than signaling a major shift in view on the US medtech supplier.

West Pharmaceutical shares in the United States remained closely watched after a fresh broker move on 05/29/2026, when Morgan Stanley lifted its price target to USD 325 while reiterating an equal-weight rating on the New York-listed stock, with the shares trading around USD 320 that day according to a summary of the bank’s report and trading data from MarketBeat and GuruFocus as of 05/29/2026.

The move keeps the focus firmly on the valuation of the US-based medical technology supplier on the NYSE, as the new target implies only modest nominal upside from the recent trading level and suggests that Morgan Stanley’s adjustment reflects refined assumptions rather than a fundamentally different view of West Pharmaceutical’s earnings trajectory.

For investors tracking US equities, the fact that a major Wall Street bank such as Morgan Stanley is fine-tuning, rather than overhauling, its target on West Pharmaceutical underscores how the company’s shares have already priced in a significant part of the growth story that the medtech group has built around containment and delivery systems for injectable medicines.

The stock traded at about USD 320 on the NYSE at midday on 05/29/2026, leaving only limited room to the revised USD 325 target and highlighting how closely the current market price in the United States shadows the latest broker valuation marker.

In the US home market, West Pharmaceutical trades under the ticker WST on the New York Stock Exchange, anchoring its primary listing firmly in the United States and placing the company within the broader American healthcare and medtech universe that is tracked by institutional and retail investors alike.

The modest gap between the Morgan Stanley target and the NYSE trading level suggests that, in the bank’s view, the risk-reward profile is balanced at current prices, with West Pharmaceutical’s operational strengths offset by the valuation premium that its US-listed shares already command within the healthcare sector.

According to the alert summarizing Morgan Stanley’s 05/29/2026 note, the price target was raised from USD 315 to USD 325 while maintaining an equal-weight rating, which effectively acknowledges incremental improvements or updated modeling inputs without recasting West Pharmaceutical as either significantly undervalued or overvalued at its present NYSE quotation.

For readers in German-speaking markets who access US equities via local trading venues, it is worth noting that West Pharmaceutical is also available on platforms such as Tradegate and other German exchanges in euro terms, providing an additional route to gain exposure to the US-listed group without trading directly on the NYSE.

The stock traded at roughly USD 320 on 05/29/2026 on the New York Stock Exchange, according to MarketBeat and GuruFocus summaries as of that date, which aligns with the narrative that the shares are hovering just below the refreshed price target set by Morgan Stanley.

Market observers often treat such fine-tuning steps from prominent US banks as incremental rather than transformational, but the timing of the Morgan Stanley move nevertheless gives an updated reference point for how Wall Street currently values West Pharmaceutical’s positioning in drug containment and delivery systems.

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: West Pharmaceutical
• Sector/industry: Healthcare equipment and medical technology for injectable drug delivery
• Headquarters/country: Exton, United States
• Core markets: North America, Europe and selected Asia-Pacific healthcare and pharmaceutical markets
• Key revenue drivers: Containment and delivery systems for injectable drugs, contract manufacturing and related analytical services
• Home exchange/listing venue: New York Stock Exchange (WST)
• Trading currency: USD

West Pharmaceutical: core business model

West Pharmaceutical focuses on designing and producing advanced containment and delivery solutions for injectable therapies, with revenue largely generated from sales of primary packaging, delivery systems and contract manufacturing services to pharmaceutical and biotech customers worldwide.

Chart technicals and 52-week range

Because West Pharmaceutical trades primarily on the NYSE under the ticker WST, chart technicians often start with the US listing when assessing trends, using price histories and volatility measures to situate the latest Morgan Stanley target adjustment within the broader performance pattern of the stock.

Over a typical 52-week observation window, analysts and technically oriented traders look at how West Pharmaceutical’s share price has moved between its yearly low and high on the NYSE, pairing this with simple indicators such as moving averages to gauge whether the stock is trading closer to the upper or lower end of its recent range and how that aligns with broker targets such as Morgan Stanley’s USD 325 level.

Conclusion

The latest Morgan Stanley move to raise its West Pharmaceutical price target from USD 315 to USD 325 while maintaining an equal-weight stance gives market participants an updated valuation yardstick, but one that still sits very close to the NYSE trading level near USD 320 on 05/29/2026.

With the shares already hovering close to that revised target, the focus for many investors in the United States and abroad will likely remain on how West Pharmaceutical executes on its core injectable drug containment and delivery franchise and how that performance feeds back into both fundamental valuations and the technical picture over the coming months.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.